secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-08-10T20:07:12+00:00
Accession:  0001437749-26-026771
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed Q2 net loss $6.6M; neflamapimod data supports Phase 3 DLB plan
-----------------------------------------------------------------------

- Net loss $6.6M vs $6.3M YoY; cash $24.9M at June 30, 2026, runway to Q3 2027.
- Grant revenue zero vs $1.8M; R&D $4.3M vs $5.1M; G&A $2.4M vs $3.3M.
- AAIC data: CDR-SB improvement 0.70 (p=0.054) in pure DLB; basal forebrain atrophy slowed (p=0.028).
- Neflamapimod awarded UK ILAP Innovation Passport; company pursuing partnership for Phase 3 DLB trial.
- Raised ~$20.5M gross in June equity financings; ended RAS enrollment, completed nfvPPA enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/0001437749-26-026771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/crvo20260810_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-026771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer